All in the head: obstacles for immune rejection of brain tumours

Walker, Paul R; Calzascia, Thomas; Dietrich, Pierre‐Yves

doi:10.1046/j.1365-2567.2002.01507.x

Cited by 51 publications

(44 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…meningioma, LGG), but HGG seems to have a relatively short progression period. In addition, glioma patients are known to have immunological defects such as abnormal delayed hypersensitivity responses, low number of circulating T-cells, decreased antibody response and impaired T-cell cytotoxicity (33,34). Our results based on prospectively collected data cannot give a conclusive answer which hypothesis might be favoured, but for HGG our data provide some support for the immune surveillance hypothesis.…”

Section: Discussionmentioning

confidence: 58%

Primary brain tumours and specific serum immunoglobulin E: a case–control study nested in the European Prospective Investigation into Cancer and Nutrition cohort

Schlehofer

Siegmund

Linseisen

et al. 2011

Allergy

View full text Add to dashboard Cite

The results, based on serum samples prospectively collected in a cohort study, provide some support for the hypothesis that individuals with allergic sensitization are at reduced risk of glioma and confirm results from previous case-control studies. DOI: https://doi.org/10.1111/j. 1398-9995.2011.02670.x Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-54311 Originally published at: Schlehofer, B; Siegmund, B; Linseisen, J; Schüz, J; Rohrmann, S; Becker, S; Michaud, D; Melin, B; Bas Bueno-de-Mesquita, H; Peeters, P H M; Vineis, P; Tjonneland, A; Olsen, A; Overvad, K; Romieu, I; Boeing, H; Aleksandrova, K; Trichopoulou, A; Bamia, C; Lagiou, P; Sacerdote, C; Palli, D; Panico, S; Sieri, S; Tumino, R; Sanchez, M-J; Rodriguez, L; Dorronsoro, M; Duell, E J; Chirlaque, M-D; Barricarte, A; Borgquist, S; Manjer, J; Gallo, V; Allen, N E; Key, T J; Riboli, E; Kaaks, R; Wahrendorf, J (2011). Primary brain tumours and specific serum immunoglobulin E: a case-control study nested in the European Prospective Investigation into Cancer and Nutrition cohort. Allergy, 66(11):1434-1441. DOI: https://doi.org/10.1111/j. 1398-9995.2011.02670 Abstract Background: Case-control studies suggest that patients with allergic diseases have a lower risk of developing glioma but not meningioma or schwannoma. However, those data can be differentially biased. Prospective studies with objective measurements of immunologic biomarkers, like immunoglobulin E (IgE), in blood obtained before cancer diagnosis could help to clarify whether an aetiological association exists.Methods: The present case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) measured specific serum IgE as a biomarker for the most common inhalant allergens in 275 glioma, 175 meningioma and 49 schwannoma cases and 963 matched controls using the ImmunoCAP specific

show abstract

Section: Discussionmentioning

confidence: 58%

Primary brain tumours and specific serum immunoglobulin E: a case–control study nested in the European Prospective Investigation into Cancer and Nutrition cohort

Schlehofer

Siegmund

Linseisen

et al. 2011

Allergy

View full text Add to dashboard Cite

show abstract

“…2G). The restoration of NKG2D expression was incomplete in serum, suggesting the presence of other modulators of NKG2D expression in these samples (4).…”

Section: Rna Interference Of Tgf-␤ In Gliomasmentioning

confidence: 90%

RNA Interference Targeting Transforming Growth Factor-β Enhances NKG2D-Mediated Antiglioma Immune Response, Inhibits Glioma Cell Migration and Invasiveness, and Abrogates TumorigenicityIn vivo

et al. 2004

View full text Add to dashboard Cite

show abstract

“…This branch of the immune system is effective at eradicating viral infections and other conditions that involve the creation of new intracellular antigens, such as cancer. Brain tumors (as well as normal brain tissue), however, strongly restrain the activity of Th1 immune reactions by means of suppressive cytokines; a physical architecture constrained to inhibit inflammation; a restricted repertoire of supportive immune cells, such as professional antigen-presenting cells; and low expression of stimulating cell surface major histocompatibility proteins (12)(13)(14). The available epidemiologic and clinical data noted above suggest that features associated with Th2-type immunity, such as allergies and high IgE levels, may help to improve anti-glioma immunity.…”

Section: Introductionmentioning

confidence: 99%

Allergy-Related Polymorphisms Influence Glioma Status and Serum IgE Levels

Wiencke

Kelsey

Moghadassi

et al. 2007

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Previous studies have shown that glioma patients report allergies less frequently than controls, harbor lower atopyassociated IgE levels, and harbor different frequencies of polymorphisms in the IL13 and IL4 pathways than controls. We sought to confirm this latter result and extend the analysis to IgE levels. Glioma patients (n = 456) and controls (n = 541) were genotyped for genetic variants in IL4, IL4R, and IL13 and tested for total IgE levels (n = 248 controls and 289 cases). Among Whites, IL4 and IL4R polymorphisms and haplotypes were neither significantly associated with IgE levels in controls nor associated with glioma status. IL13 R110G and C-1112T were associated with increased IgE levels in controls (P < 0.001 and P = 0.04, respectively), and IL13 C-1112T was inversely associated with case-control status (P = 0.05, test for trend in dose model). An IL4R haplotype was borderline associated with increased risk in case-control analysis [odds ratio (OR), 1.5; 95% confidence interval (95% CI), 1.0-2.3]. In addition, a rare haplotype for IL4 was associated with decreased risk (OR, 0.23; 95% CI, 0.07-0.83), and a common haplotype in IL13 was associated with decreased risk (OR, 0.73; 95% CI, 0.53-1.00). Our data provide evidence for a role of IL13 polymorphisms on IgE levels and a role for IL4, IL4R, and IL13 haplotypes on case-control status. We did not find any evidence that the interleukin (IL) polymorphisms exerted their effect on glioma risk via their effects on IgE levels. Further exploration of immune susceptibility factors, including genetics, in glioma etiology is advisable. (Cancer Epidemiol Biomarkers Prev 2007;16(6):1229 -35)

show abstract

All in the head: obstacles for immune rejection of brain tumours

Cited by 51 publications

References 131 publications

Primary brain tumours and specific serum immunoglobulin E: a case–control study nested in the European Prospective Investigation into Cancer and Nutrition cohort

Primary brain tumours and specific serum immunoglobulin E: a case–control study nested in the European Prospective Investigation into Cancer and Nutrition cohort

RNA Interference Targeting Transforming Growth Factor-β Enhances NKG2D-Mediated Antiglioma Immune Response, Inhibits Glioma Cell Migration and Invasiveness, and Abrogates TumorigenicityIn vivo

Allergy-Related Polymorphisms Influence Glioma Status and Serum IgE Levels

Contact Info

Product

Resources

About